1 week Ago By Defense World Staff
Invesco Ltd. boosted its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by 451.
6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 203,404 shares of the company’s stock after buying an additional 166,526 shares during the period. Invesco Ltd.
’s holdings in Dr. Reddy’s Laboratories were worth $3,212,000 as of its most recent SEC filing. Several other institutional investors also recently bought and sold shares of RDY.
Geode Capital Management LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 109.3% in the third quarter.
Geode Capital Management LLC now owns 13,254 shares of the company’s stock valued at $1,053,000 after acquiring an additional 6,920 shares in the last quarter. Virtu Financial LLC purchased a new stake in Dr. Reddy’s Laboratories in the 3rd quarter valued at approximately $276,000.
World Investment Advisors LLC acquired a new position in Dr. Reddy’s Laboratories during the 3rd quarter worth approximately $3,459,000. B.
Riley Wealth Advisors Inc. purchased a new position in shares of Dr. Reddy’s Laboratories during the 3rd quarter worth approximately $490,000.
Finally, Confluence Investment Management LLC lifted its holdings in shares of Dr. Reddy’s Laboratories by 400.0% in the 4th quarter.
Confluence Investment Management LLC now owns 18,290 shares of the company’s stock valued at $289,000 after buying an additional 14,632 shares during the period. 3.85% of the stock is owned by institutional investors and hedge funds.
Dr. Reddy’s Laboratories Trading Down 1.4 %Shares of RDY stock opened at $13.
81 on Monday. The business’s fifty day moving average price is $13.17 and its 200 day moving average price is $14.
20. The firm has a market capitalization of $11.53 billion, a PE ratio of 21.
99 and a beta of 0.51. The company has a debt-to-equity ratio of 0.
02, a current ratio of 1.92 and a quick ratio of 1.38.
Dr. Reddy’s Laboratories Limited has a 1-year low of $12.26 and a 1-year high of $16.
89. Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) last posted its quarterly earnings results on Thursday, January 23rd.
The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.
01. Dr. Reddy’s Laboratories had a net margin of 17.
25% and a return on equity of 17.87%. As a group, sell-side analysts forecast that Dr.
Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year. Dr.
Reddy’s Laboratories Profile (Free Report)Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments.
The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.Featured ArticlesFive stocks we like better than Dr. Reddy’s LaboratoriesFinancial Services Stocks InvestingTexas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryWhat Percentage Gainers Tell Investors and Why They Don’t Tell the Whole StoryO’Reilly Automotive: An Anytime Buy for Buy-and-Hold InvestorsHigh Dividend REITs: Are They an Ideal Way to Diversify?Chipotle Mexican Grill Serves Smoking Hot Entry Point in Q2Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report)..
